Genus PLC - Asset Resilience Ratio

Latest as of December 2023: -1.07%

Genus PLC (GNS) has an Asset Resilience Ratio of -1.07% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Genus PLC to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX-11.30 Million

≈ $-1.37K USD Cash + Short-term Investments

Total Assets

GBX1.05 Billion

≈ $128.23K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2023)

This chart shows how Genus PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Genus PLC asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Genus PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Genus PLC long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX-11.30 Million	-1.07%
Total Liquid Assets	GBX-11.30 Million	-1.07%

Asset Resilience Insights

Limited Liquidity: Genus PLC maintains only -1.07% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Genus PLC Industry Peers by Asset Resilience Ratio

Compare Genus PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Celldex Therapeutics Inc NASDAQ:CLDX	Biotechnology	81.32%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Savara Inc NASDAQ:SVRA	Biotechnology	68.30%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%

Annual Asset Resilience Ratio for Genus PLC (2006–2023)

The table below shows the annual Asset Resilience Ratio data for Genus PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	-1.30%	GBX-13.10 Million ≈ $-1.59K	GBX1.01 Billion ≈ $122.58K	-0.24pp
2022-06-30	-1.06%	GBX-10.80 Million ≈ $-1.31K	GBX1.02 Billion ≈ $123.85K	-0.85pp
2021-06-30	-0.21%	GBX-1.80 Million ≈ $-219.01	GBX851.00 Million ≈ $103.54K	0.00pp
2020-06-30	-0.21%	GBX-1.80 Million ≈ $-219.01	GBX855.40 Million ≈ $104.08K	-0.53pp
2018-06-30	0.32%	GBX2.50 Million ≈ $304.18	GBX789.20 Million ≈ $96.02K	+0.15pp
2017-06-30	0.16%	GBX1.30 Million ≈ $158.17	GBX797.60 Million ≈ $97.04K	+0.08pp
2016-06-30	0.08%	GBX600.00K ≈ $73.00	GBX739.10 Million ≈ $89.93K	-0.03pp
2015-06-30	0.11%	GBX700.00K ≈ $85.17	GBX644.30 Million ≈ $78.39K	+0.18pp
2012-06-30	-0.07%	GBX-400.00K ≈ $-48.67	GBX588.20 Million ≈ $71.57K	+0.10pp
2010-06-30	-0.17%	GBX-900.00K ≈ $-109.50	GBX542.40 Million ≈ $65.99K	+0.18pp
2009-06-30	-0.34%	GBX-1.70 Million ≈ $-206.84	GBX497.90 Million ≈ $60.58K	+0.23pp
2008-06-30	-0.57%	GBX-2.50 Million ≈ $-304.18	GBX436.00 Million ≈ $53.05K	+0.46pp
2007-06-30	-1.03%	GBX-4.50 Million ≈ $-547.52	GBX434.80 Million ≈ $52.90K	-0.38pp
2006-06-30	-0.66%	GBX-3.00 Million ≈ $-365.01	GBX456.30 Million ≈ $55.52K	--

pp = percentage points

About Genus PLC

LSE:GNS UK Biotechnology

Market Cap

$16.90 Million

GBX138.94 Billion GBX

Market Cap Rank

#25726 Global

#285 in UK

Share Price

GBX2092.00

Change (1 day)

-1.97%

52-Week Range

GBX1966.00 - GBX3170.00

All Time High

GBX5805.43